CLAIMS

1. The use of three or more (i.e. 3, 4, 5, 6, 7, 8 or 9) Neuroaid2 components for activating K_{ATP} channels, wherein the three or more Neuroaid2 components are selected from the group consisting of:

   i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);
   ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;
   iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);
   iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);
   v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);
   vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);
   vii. Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong);
   viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and
   ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis),

   and wherein said three or more Neuroaid2 components comprise: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

2. A method of treating a disease or disorder in a patient wherein the disease or disorder can be treated by activating K_{ATP} channels, wherein the method comprises (and optionally consists of) administering three or more Neuroaid2 components (3, 4, 5, 6, 7, 8 or 9 Neuroaid2 components) to the patient, wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);
ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;
iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);
iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);
v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);
vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);
vii. Chuanxiong; preferably the rhizome thereof (i.e. rhizoma chuanxiong);
viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and
ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis)

and wherein said three or more Neuroaid2 components comprise: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

3. Three or more Neuroaid2 components (3, 4, 5, 6, 7, 8 or 9 Neuroaid2 components) for use in a method of treating a disease or disorder in a patient wherein the disease or disorder can be treated by activating K_{ATP} channels, and wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);
ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;
iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);
iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);

v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);

vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);

vii. Chuanxiong; preferably the rhizome thereof (i.e. rhizoma chuanxiong);

viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and

ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis)

and wherein said three or more Neuroaid2 components comprise: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

4. The use of three or more Neuroaid2 components (3, 4, 5, 6, 7, 8 or 9 Neuroaid2 components) in the manufacture of a medicament for treating a disease or disorder wherein the disease or disorder can be treated by activating K_{ATP} channels and wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);

ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;

iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);

iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);

v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);

vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);

vii. Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong);

viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and

ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis).

and wherein said three or more Neuroaid2 components comprise: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

5. A composition or kit comprising (and optionally consisting of as active ingredients) three or more Neuroaid2 components (3, 4, 5, 6, 7, 8 or 9 Neuroaid2 components), wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);
ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;
iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);
iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);
v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);
vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);
vii. Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong);
viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and
ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis)

and wherein said three or more Neuroaid2 components comprise: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

6. The use according to claim 1 or 4, the method according to claim 2, the three or more Neuroaid2 components according to claim 3, or the composition or kit according to claim 5, wherein the selected Neuroaid2 components comprise (and optionally consist of):

(a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae); or

(b) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome).

7. The use according to claim 6, the method according to claim 6, the three or more Neuroaid2 components according to claim 6, or the composition or kit according to claim 6, wherein the selected Neuroaid2 components is all nine Neuroaid2 components.

8. A method according to any one of claims 2, 6 or 7, the three or more Neuroaid2 components according to any one of claims 3, 6 or 7, or the use according to any one of claims 1, 4, 6 or 7, wherein the treating or the disease or disorder is selected from the group consisting of:

prevention of ischemic or reperfusion injury; treatment of hyperinsulemia or hyperinsulinism; treatment of hypoglycemia; prevention of the transition from prediabetes to diabetes; treatment of type II diabetes; correction of the defects in insulin secretion and insulin sensitivity contributing to prediabetes and type II diabetes; preservation of pancreatic function in type I diabetics; treatment of hyperlipidemia; prevention of weight gain in individuals who are predisposed to obesity; treatment of obesity; treatment of metabolic syndrome (or syndrome X); treatment of polycystic ovary syndrome; treat weight gain, dyslipidemia, or impairment of glucose tolerance in subjects treated with antipsychotics drugs; prevent weight gain, dyslipidemia, or impairment of glucose tolerance in subjects treated with antipsychotics drugs; and treatment of any disease where hyperlipidemia, hyperinsulemia, hyperinsulinism,

hyperlipidemia, hyperphagia or obesity are contributing factors to the severity or progression of the disease, including but not limited to, Prader Willi Syndrome, Froelich's syndrome, Cohen syndrome, Summit Syndrome, Alstrom, Syndrome, Borjesen Syndrome, Bardet-Biedl Syndrome, hyperlipoproteinemia type I, II, III, and IV; hypertension; neurodegeneration; stroke; ischemia; epilepsy; pain; overactive bladder; urinary incontinence; irritable bowel syndrome; hair loss; baldness; alopecia; male erectile dysfunction; female sexual disorders; premature labor; benign prostate hyperplasia (BPH); dysmenorrheal; coronary artery disease; angina; airway hyperactivity; eating disorders; use of the three or more Neuroaid2 components as an anti-neoplastic agent (e.g. for treating brain cancers); skeletal muscle diseases such as myotonia congenita and hyperkalemic paralysis; use of the three or more Neuroaid2 components as a vasodilator; hypertension; asthma; stopping the normal heartbeat in order to perform cardiac, aortic, neurovascular and cardiopulmonary organ transplant surgery and other related operations; impotence; treatment of arrhythmia; diabetes (e.g. diabetes mellitus type I or type II); insulin resistance; treating sensitive human skin; heart failure; peripheral vascular disorders; insulinoma; congenital hyperinsulinism; retinal ischemia; reducing the consumption of fat-containing foods; hypoglycaemia; depression or depression-related mood disorders; neuroconditioning (e.g. in a patient at risk of an insult such as, for example, an insult resulting from any of the following conditions: ischemic, transient or permanent, focal or generalized; seizure, focal or generalized; inflammatory; toxic (e.g. radiation, chemical, or drug-related); neuroprotection; immunologic; infectious; metabolic, nutritional; traumatic; compressive; neoplastic; degenerative; genetic, congenital; and procedural (including for example those requiring general anesthesia, clamping of major vessels, or opening of the cranial cavity).

9. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to claim 8, wherein said disease or disorder is urinary incontinence, obesity or hypertension.

10. A method according to claim 9, the three or more Neuroaid2 components according to claim 9, or the use according to claim 9, wherein said disease or disorder is urinary incontinence.

11. A method according to claim 9, the three or more Neuroaid2 components according to claim 9, or the use according to claim 9, wherein said disease or disorder is obesity.

12. A method according to claim 9, the three or more Neuroaid2 components according to claim 9, or the use according to claim 9, wherein said disease or disorder is hypertension.

13. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to claim 8, wherein said treating is neuroconditioning.

14. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to any claim 8, wherein said treating or said disease or disorder is selected from the group consisting of: prevention of ischemic or reperfusion injury; treatment of hyperinsulemia or hyperinsulinism; treatment of hypoglycemia; prevention of the transition from prediabetes to diabetes; treatment of type II diabetes; correction of the defects in insulin secretion and insulin sensitivity contributing to prediabetes and type II diabetes; preservation of pancreatic function in type I diabetics; treatment of hyperlipidemia; prevention of weight gain in individuals who are predisposed to obesity; treatment of obesity; treatment of metabolic syndrome (or syndrome X); treatment of polycystic ovary syndrome; treat weight gain, dyslipidemia, or impairment of glucose tolerance in subjects treated with antipsychotics drugs; prevent weight gain, dyslipidemia, or impairment of glucose tolerance in subjects treated with antipsychotics drugs; and treatment of any disease where hyperlipidemia, hyperinsulemia, hyperinsulinism, hyperlipidemia, hyperphagia or obesity are contributing factors to the severity or progression of the disease, including but not limited to, Prader Willi Syndrome, Froelich's syndrome, Cohen syndrome, Summit Syndrome, Alstrom, Syndrome, Borjesen Syndrome, Bardet-Biedl Syndrome, and hyperlipoproteinemia type I, II, III, and IV.

15. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to any claim 8, wherein said disease or disorder is selected from the group consisting of: hypertension, neurodegeneration, stroke, ischemia, epilepsy, pain, overactive bladder, urinary incontinence, irritable bowel syndrome, hair loss, baldness, alopecia, male erectile dysfunction, female sexual disorders, premature labor, benign prostate hyperplasia (BPH), dysmenorrhea, coronary artery disease, angina, and airway hyperactivity eating disorders.

16. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to claim 8, wherein said treating or said disease or disorder is

selected from: use of the three or more Neuroaid2 components as a vasodilator, hypertension, asthma, urinary incontinence, stopping the normal heartbeat in order to perform cardiac, aortic, neurovascular and cardiopulmonary organ transplant surgery and other related operations, treating sensitive human skin, and impotence.

17. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to any claim 8, wherein said treating or said disease or disorder is selected from: use of the three or more Neuroaid2 components as a vasodilator, hypertension, asthma, treatment of arrhythmia, diabetes (e.g. diabetes mellitus type I or type II), obesity, metabolic syndrome, syndrome X, insulin resistance, stopping the normal heartbeat in order to perform cardiac, aortic, neurovascular and cardiopulmonary organ transplant surgery and other related operations, treating sensitive human skin, heart failure, and impotence.

18. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to any claim 8, wherein said treating or said disease or disorder is selected from: use of the three or more Neuroaid2 components as a vasodilator, hypertension, peripheral vascular disorders, insulinoma, congenital hyperinsulinism, metabolic syndrome, retinal ischemia, diabetes, obesity, treatment of syndrome X, reducing the consumption of fat-containing foods, and hypoglycaemia.

19. A method according to claim 8, the three or more Neuroaid2 components according to claim 8, or the use according to any claim 8, wherein said treating of said disease or disorder is selected from: depression or depression-related mood disorders; and selectively delivering a medicament to a malignant tumor in the brain or to a tumor elsewhere in the body of a mammalian subject.

20. A method of treating a disease or disorder in a patient wherein the disease or disorder can be treated by activating K_{ATP} channels (e.g. urinary incontinence, obesity, hypertension, or a disease or disorder which would benefit from neuroprotection or neuroconditioning), wherein the method comprises administering a composition to the patient comprising the nine Neuroaid2 components, i.e.:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);

ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;

iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);

iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);

v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);

vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);

vii. Chuanxiong; preferably the rhizome thereof (i.e. rhizoma chuanxiong);

viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and

ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis)

and wherein said nine Neuroaid2 components are optionally administered in about the same ratios as employed in the MLC901 composition.

21. A composition (e.g. a pharmaceutical composition) or kit according to claim 5, wherein said composition or kit consists of as active ingredients the following components: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);

and optionally one or more further active ingredients which are not selected from the group consisting of: Salviae Miltiorrhizae (Red Sage or Dan Shen); Prunus persica (Peach or Tao ren); Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi); acori tatarinowii (grassleaf sweetflag or Shichangpu); Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao); and Carthamus tinctorius (Safflower or HongHua).

22. A composition (e.g. a pharmaceutical composition) or kit according to claim 5, wherein said composition or kit consists of as active ingredients the following components: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);

and optionally one or more further active ingredients which are not selected from the group consisting of: Salviae Miltiorrhizae (Red Sage or Dan Shen); Prunus persica (Peach or Tao ren); acori tatarinowii (grassleaf sweetflag or Shichangpu); Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao); and Carthamus tinctorius (Safflower or HongHua).

23. A composition (e.g. a pharmaceutical composition) or kit according to claim 5, wherein said composition or kit consists of as active ingredients the following components: Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);

and optionally one or more further active ingredients which are not selected from the group consisting of: Prunus persica (Peach or Tao ren); Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi); acori tatarinowii (grassleaf sweetflag or Shichangpu); Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao); and Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof.

24. A composition or kit according to any one of claims 5, 6, 7, 21, 22 or 23 for use in a method as described herein, for use in the manufacture of a medicament as described herein, or for any other use described herein.

25. A composition or kit according to claim 5, 6, 7, 21, 22 or 23 for use in a method of providing neuroprotection, neuroconditioning, treating obesity, treating hypertension, treating urinary incontinence or treating stroke, or for use in the manufacture of a medicament for use in a method of providing neuroprotection, neuroconditioning, treating obesity, treating hypertension, treating urinary incontinence or treating stroke.

CLAIMS

1. The use of three or more Neuroaid2 components (3, 4, 5, 6, 7, 8 or 9 Neuroaid2 components) in the manufacture of a medicament for treating a disease or disorder, wherein the disease or disorder can be treated by activating K_{ATP} channels, and wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);
ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;
iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);
iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);
v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);
vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);
vii. Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong);
viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and
ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis).

and wherein said selected three or more Neuroaid2 components consist of: (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae); or

wherein said selected three or more Neuroaid2 components comprise: (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

2. Three or more Neuroaid2 components (3, 4, 5, 6, 7, 8 or 9 Neuroaid2 components) for use in a method of treating a disease or disorder in a patient wherein the disease or disorder can be treated by activating K_{ATP} channels, and wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);
ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;
iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);
iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);
v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);
vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);
vii. Chuanxiong; preferably the rhizome thereof (i.e. rhizoma chuanxiong);
viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and
ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis)

and wherein said selected three or more Neuroaid2 components consist of (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae); or

wherein said selected three or more Neuroaid2 components comprise: (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

3. A composition or kit comprising (and optionally consisting of as active ingredients) three or more Neuroaid2 components (3, 4, 5, 6, 7, 8 or 9 Neuroaid2 components), wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);
ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;
iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);
iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);
v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);
vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);
vii. Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong);
viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and
ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis)

and wherein said selected three or more Neuroaid2 components consist of: (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae); or

wherein said selected three or more Neuroaid2 components comprise: (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

4. The composition or kit of claim 3 wherein said composition or kit is for activating K_{ATP} channels, or is for use in a method of treating a disease or disorder in a patient wherein the disease or disorder can be treated by activating KATP channels.

5. The use of three or more (i.e. 3, 4, 5, 6, 7, 8 or 9) Neuroaid2 components for activating K_{ATP} channels, wherein the three or more Neuroaid2 components are selected from the group consisting of:

i. Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome);

ii. Prunus persica (Peach or Tao ren), preferably the seed thereof;

iii. Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);

iv. acori tatarinowii (grassleaf sweetflag or Shichangpu), preferably the rhizome thereof (i.e. rhizoma acori tatarinowii);

v. Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali);

vi. Paeoniae Rubra (Red Peony, Paeonia lactiflora Pall, Paeonia veitchii Lynch or Chi Shao), preferably the root (i.e. radix paeoniae rubra);

vii. Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong);

viii. Carthamus tinctorius (Safflower or HongHua), preferably the flower thereof; and

ix. angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis),

and wherein said selected three or more Neuroaid2 components consist of (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae); or

wherein said selected three or more Neuroaid2 components comprise: (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); and (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali).

and wherein said use is optionally *in vitro* or *ex vivo*.

6. The use of claim 1 or claim 5, or the three or more Neuroaid2 components of claim 2, or the composition or kit of claim 3 or 4, wherein said selected three or more Neuroaid2 components comprise:

(i) (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae); or

(ii) (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome).

7. The use of claim 6, or the three or more Neuroaid2 components of claim 6, or the composition or kit of claim 6, wherein said selected three or more Neuroaid2 components consist of

(i) (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Polygalae (thinleaf milkwort, Polygala tenuifolia Willd., Polygala sibirica L. or Yuanzhi), preferably the root thereof (i.e. radix polygalae);

(ii) (a) Chuanxiong, preferably the rhizome thereof (i.e. rhizoma chuanxiong); (b) angelicae sinensis (Chinese Angelica or DanGui), preferably the root (i.e. radix angelicae sinensis); (c) Astragali (Membranous Milkvetch or Huang Qi), preferably the root (i.e. radix astragali); and (d) Salviae Miltiorrhizae (Red Sage or Dan Shen), for example the root (radix) and/or rhizome (rhizoma) (in preferred embodiments, the radix, or radix et rhizome); or

(iii) all nine Neuroaid2 components.

8. The use of any one of claims 1, or claim 6 or 7 when dependent from claim 1, wherein:

(i) the medicament or the treating does not comprise (a) Buthus martensii (scorpion or Quanxie); (b) Eupolyphaga Seu Seteleophaga (ground beetle, Eupolyphaga sinensis Walker,

Steleophaga plancyi or Tubiechong); (c) Calculus Bovis Artifactus (Natural or Artificial cow-bezoar or Rengong Niuhuang); (d) Cornu Saigae Tataricae (Antelope Horn or Lingyangjiao); or (e) leeches (Hirudo, Whitmania pigra Whitman, Hirudo nipponica Whitman Whitmania acranulata Whitman or Shuizhi);

(ii) the medicament or the treating does not comprise any further Traditional Chinese Medicine (TCM); or

(iii) the medicament or the treating consists of as active ingredients the said selected three or more Neuroaid2 components, optionally with one or more further active ingredients which is not a TCM ingredient and wherein said one or more further active ingredients is for simultaneous, separate or sequential administration with said three or more selected Neuroaid2 components.

9. The three or more Neuroaid2 components of any one of claims 2, 6 or 7 wherein:

(i) said method of treating does not comprise the use of: (a) Buthus martensii (scorpion or Quanxie); (b) Eupolyphaga Seu Seteleophaga (ground beetle, Eupolyphaga sinensis Walker, Steleophaga plancyi or Tubiechong); (c) Calculus Bovis Artifactus (Natural or Artificial cow-bezoar or Rengong Niuhuang); (d) Cornu Saigae Tataricae (Antelope Horn or Lingyangjiao); or (e) leeches (Hirudo, Whitmania pigra Whitman, Hirudo nipponica Whitman Whitmania acranulata Whitman or Shuizhi);

(ii) said method of treating does not comprise the use of any further Traditional Chinese Medicine (TCM); or

(iii) the active ingredients in said method of treating consists of the said selected three or more Neuroaid2 components, optionally with one or more further active ingredients which is not a TCM ingredient and wherein said one or more further active ingredients is for simultaneous, separate or sequential administration with said three or more selected Neuroaid2 components.

10. The composition or kit of any one of claims 3, 4, 6 or 7, wherein:

(i) said composition or kit does not comprise: (a) Buthus martensii (scorpion or Quanxie); (b) Eupolyphaga Seu Seteleophaga (ground beetle, Eupolyphaga sinensis Walker, Steleophaga plancyi or Tubiechong); (c) Calculus Bovis Artifactus (Natural or Artificial cow-bezoar or Rengong Niuhuang); (d) Cornu Saigae Tataricae (Antelope Horn or Lingyangjiao); or (e)

leeches (Hirudo, Whitmania pigra Whitman, Hirudo nipponica Whitman Whitmania acranulata Whitman or Shuizhi);

(ii) said composition or kit does not comprise any further Traditional Chinese Medicine (TCM); or

(iii) said composition or kit consists of as active ingredients the said selected three or more Neuroaid2 components, optionally with one or more further active ingredients which is not a TCM ingredient and wherein said one or more further active ingredients is for simultaneous, separate or sequential administration with said selected three or more Neuroaid2 components.

11. The use of any one of claims 5, or claim 6 or 7 when dependent from claim 5, wherein:

(i) said activating does not comprise the use of: (a) Buthus martensii (scorpion or Quanxie); (b) Eupolyphaga Seu Seteleophaga (ground beetle, Eupolyphaga sinensis Walker, Steleophaga plancyi or Tubiechong); (c) Calculus Bovis Artifactus (Natural or Artificial cow-bezoar or Rengong Niuhuang); (d) Cornu Saigae Tataricae (Antelope Horn or Lingyangjiao); or leeches (Hirudo, Whitmania pigra Whitman, Hirudo nipponica Whitman Whitmania acranulata Whitman or Shuizhi);

(ii) said activating does not comprise the use of any further Traditional Chinese Medicine (TCM); or

(iii) the said selected three or more Neuroaid2 components consists of the active ingredients in said activating, optionally with one or more further active ingredients which is not a TCM ingredient and wherein said one or more further active ingredients is for simultaneous, separate or sequential use with said selected three or more Neuroaid2 components.

12. The use according to any one of claims 1, 6, 7 or 8, the three or more Neuroaid2 components according to any one of claims 2, 6, 7 or 9, or the composition or kit according to any one of claims 4, 6, 7 or 10, wherein said disease or disorder is selected from the group consisting of: stroke; a neurological disorder (e.g. a neurodegenerative disease (such as Alzheimer's or Parkinson's) or brain trauma); cerebral infarct; a condition related to neuroplasticity; nervous system trauma; cardiac arrest; subarachnoid hemorrhage; cardiovascular disease; apoplexy; a psychiatric indication (e.g. an anxiety disorder, schizophrenia, depression, or post-natal depression); natural aging; traumatic brain cell death and other neurologic manifestations such as amnesia, back pain, vertigo, unconsciousness, phantom limb, olfaction disorders, neck pain, headache, migranes, spasm and speech

disorders; neurodegeneration; a nervous system injury or disease (e.g. amyotrophic lateral sclerosis (ALS) and senile dementia); a degenerative disease; rheumatoid arthritis; a muscle degenerative disorder; kidney diseases; and liver diseases.

13. The use according to claim 12, the three or more Neuroaid2 components according to 12, or a composition or kit according to claim 12, wherein the disease or disorder is stroke and said treating is for treating a patient who is at risk of a stroke, a patient who has just had a stroke (e.g. within the past 96, 84, 72, 60, 48, 36, or 12 hours), or for stroke recovery.

14. The use according to any one of claims 1, 6, 7 or 8, the three or more Neuroaid2 components according to any one of claims 2, 6, 7 or 9, or the composition or kit according to any one of claims 4, 6, 7 or 10, wherein said treating is for providing neuroprotection, or for promoting neuronal outgrowth and proliferation of neurons or stem cells (such as in injured or diseased tissues).

15. The use according to claim 14, the three or more Neuroaid2 components according to 14, or the composition or kit according to claim 14, wherein the neuroprotection is against a factor selected from the group consisting of: stroke; neurodegeneration e.g. a neurodegenerative disease such as Alzheimer's; dementia (e.g., Alzheimer's disease, Parkinson's disease, Huntinton's chorea and spinocerebreallar degeneration); a cerebrovascular disorder; injury to the central (brain or spinal cord) and/or peripheral nervous system (e.g. traumatic brain injury); ischemia (e.g. global or focal ischemia); cardiovascular disease; myocardial infarction; a psychiatric disorder (e.g. depression or schizophrenia); cancer of the neural system; impaired myelination of nerve fibers; postischaemic damage, e.g. resulting from a stroke; multiinfarct dementia; multiple sclerosis; nerve degeneration associated with diabetes mellitus; neuro-muscular degeneration; natural aging; Huntington's disease; and migraines.

16. The use according to any one of claims 1, 6, 7 or 8, the three or more Neuroaid2 components according to any one of claims 2, 6, 7 or 9, or the composition or kit according to any one of claims 4, 6, 7 or 10, wherein the treating of the disease or disorder is selected from the group consisting of:

treatment of obesity or prevention of weight gain in individuals who are predisposed to obesity; prevention of ischemic or reperfusion injury; treatment of hyperinsulemia or

hyperinsulinism; treatment of hypoglycemia; prevention of the transition from prediabetes to diabetes; treatment of type II diabetes; correction of the defects in insulin secretion and insulin sensitivity contributing to prediabetes and type II diabetes; preservation of pancreatic function in type I diabetics; treatment of hyperlipidemia; treatment of metabolic syndrome (or syndrome X); treatment of polycystic ovary syndrome; treat weight gain, dyslipidemia, or impairment of glucose tolerance in subjects treated with antipsychotics drugs; prevent weight gain, dyslipidemia, or impairment of glucose tolerance in subjects treated with antipsychotics drugs; and treatment of any disease where hyperlipidemia, hyperinsulemia, hyperinsulinism, hyperlipidemia, hyperphagia or obesity are contributing factors to the severity or progression of the disease, including but not limited to, Prader Willi Syndrome, Froelich's syndrome, Cohen syndrome, Summit Syndrome, Alstrom, Syndrome, Borjesen Syndrome, Bardet-Biedl Syndrome, hyperlipoproteinemia type I, II, III, and IV; hypertension; neurodegeneration; stroke; ischemia; a disease or disorder which would benefit from neuroprotection, neuroconditioning, or the promotion of neuronal outgrowth and proliferation; epilepsy; pain; overactive bladder; urinary incontinence; irritable bowel syndrome; hair loss; baldness; alopecia; male erectile dysfunction; female sexual disorders; premature labor; benign prostate hyperplasia (BPH); dysmenorrheal; coronary artery disease; angina; airway hyperactivity; eating disorders; use of the three or more Neuroaid2 components as an anti-neoplastic agent (e.g. for treating brain cancers); skeletal muscle diseases such as myotonia congenita and hyperkalemic paralysis; use of the three or more Neuroaid2 components as a vasodilator; hypertension; asthma; stopping the normal heartbeat in order to perform cardiac, aortic, neurovascular and cardiopulmonary organ transplant surgery and other related operations; impotence; treatment of arrhythmia; diabetes (e.g. diabetes mellitus type I or type II); insulin resistance; treating sensitive human skin; heart failure; peripheral vascular disorders; insulinoma; congenital hyperinsulinism; retinal ischemia; reducing the consumption of fat-containing foods; hypoglycaemia; depression or depression-related mood disorders; neuroconditioning (e.g. in a patient at risk of an insult such as, for example, an insult resulting from any of the following conditions: ischemic, transient or permanent, focal or generalized; seizure, focal or generalized; inflammatory; toxic (e.g. radiation, chemical, or drug-related); neuroprotection; immunologic; infectious; metabolic, nutritional; traumatic;

compressive; neoplastic; degenerative; genetic, congenital; and procedural (including for example those requiring general anesthesia, clamping of major vessels, or opening of the cranial cavity).

17. The use according to claim 16, the three or more Neuroaid2 components according to 16, or the composition or kit according to claim 16, wherein said disease or disorder is obesity, hypertension, or urinary incontinence.

18. The use according to any one of claims 1, 6, 7 or 8, the three or more Neuroaid2 components according to any one of claims 2, 6, 7 or 9, or the composition or kit according to any one of claims 4, 6, 7 or 10 wherein said treating is for providing neuroconditioning (e.g. in a patient at risk of an insult such as, for example, an insult resulting from any of the following: ischemic, transient or permanent, focal or generalized; seizure, focal or generalized; inflammatory; toxic; immunologic; infectious; metabolic, nutritional; traumatic; compressive; neoplastic; degenerative; genetic, congenital; and procedural (including for example those requiring general anesthesia, clamping of major vessels, or opening of the cranial cavity).

19. The composition or kit according to any one of claims 3, 4, 6, 7, or 10 wherein said composition or kit is for use in a method of treating stroke, providing neuroprotection, neuronal outgrowth and proliferation, neuroconditioning, treating hypertension, treating urinary incontinence, treating obesity, or for the general well being of neurons, or for use as a dietary supplement to provide nutrition to healthy individuals, or wherein said composition or kit is for use in the manufacture of a medicament for use in treating stroke, providing neuroprotection, neuronal outgrowth and proliferation, neuroconditioning, treating obesity, treating hypertension, treating urinary incontinence, for the general well being of neurons, or for use as a dietary supplement to provide nutrition to healthy individuals.

20. The composition or kit according to any one of claims 4, 6, 7 or 10, or the use according to any one of claims 5, 6, 7 or 11, wherein said activating K_{ATP} channels is for: (i) activating K_{ATP} channels in smooth muscle cells (e.g. vascular smooth muscle cells, smooth muscle cells of the bladder), cardiac myocytes, pancreatic beta cells, adipose tissue cells, skeletal muscle cells, or cells which are not neuronal cells; (ii) treating a disease or disorder as set forth in any one of claims 12, 13, 16 or 17; or (iii) providing neuroprotection, promoting neuronal outgrowth and proliferation of neurons or stem cells, or providing neuroconditioning.

21. The composition according to any one of the preceding claims which specifies a composition, or any one of the preceding claims which refers to a composition, wherein said composition is a pharmaceutical composition, and wherein said pharmaceutical composition optionally comprises a pharmaceutically acceptable additive, carrier or diluent.

22. The composition or kit according to any one of the preceding claims which specifies a composition or kit, wherein said composition or kit is for use in a method as described herein, is for use in the manufacture of a medicament as described herein, or is for any other use described herein.